A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.
de Bono JS, Williams A, Melero I, Jayaram A, Hawley JE, Doger de Speville B, Moreno I, Castellano D, Reig Ò, Knapen DG, Anguera G, Martinez J, Gort E, de Jonge M, Alonso-Romero JL, Boni V, Perez-Gracia JL, Falcon A, de Groot DJ, Pierce AJ, Leishman AJ, Lloyd P, Bartlett PD, Bland-Ward P, Chau A, Song M, Duffy K, Hashimoto K, de Vries E.
de Bono JS, et al. Among authors: reig o.
Clin Cancer Res. 2025 Aug 14;31(16):3388-3399. doi: 10.1158/1078-0432.CCR-24-3581.
Clin Cancer Res. 2025.
PMID: 40094417
Clinical Trial.